Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Current Liabilities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Total Current Liabilities readings, the most recent being $16.4 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 4.86% to $16.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, up 4.86% year-over-year, with the annual reading at $16.4 million for FY2025, 4.86% up from the prior year.
  • Total Current Liabilities hit $16.4 million in Q4 2025 for Terns Pharmaceuticals, up from $15.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $16.4 million in Q4 2025 and bottomed at $5.8 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $10.4 million, with a median of $10.9 million recorded in 2024.
  • The largest annual shift saw Total Current Liabilities crashed 70.12% in 2021 before it surged 135.57% in 2023.
  • Terns Pharmaceuticals' Total Current Liabilities stood at $6.8 million in 2021, then grew by 24.16% to $8.5 million in 2022, then surged by 41.05% to $11.9 million in 2023, then surged by 31.03% to $15.6 million in 2024, then increased by 4.86% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Total Current Liabilities are $16.4 million (Q4 2025), $15.4 million (Q3 2025), and $12.9 million (Q2 2025).